Richard Johnson, MD, discusses the results of a study from ASN Kidney Week 2023 detailing the effects of urate-lowering therapy on blood pressure among patients with gout.
AUSTIN, Texas —Results from a poster presentation here showed that patients with uncontrolled gout treated with the combined therapy of pegloticase and methotrexate saw a reduction in gout symptoms as well as a stable eGFR.Twelve-month data from the MIRROR trial showed a higher response rate among patients with chronic kidney disease when pegloticase (Krystexxa, Horizon Pharmaceuticals) was
MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the. | November 5, 2022